Sign up to our newsletter Subscribe
The Future of Global Health Procurement: Issues around Pricing Transparency

Sign up to our newsletter Subscribe
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.
An error has occurred, please try again later.